dc.contributor.author | Clarke, NW | |
dc.contributor.author | Ali, A | |
dc.contributor.author | Ingleby, FC | |
dc.contributor.author | Hoyle, A | |
dc.contributor.author | Amos, CL | |
dc.contributor.author | Attard, G | |
dc.contributor.author | Brawley, CD | |
dc.contributor.author | Calvert, J | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Cook, A | |
dc.contributor.author | Cross, W | |
dc.contributor.author | Dearnaley, DP | |
dc.contributor.author | Douis, H | |
dc.contributor.author | Gilbert, D | |
dc.contributor.author | Gillessen, S | |
dc.contributor.author | Jones, RJ | |
dc.contributor.author | Langley, RE | |
dc.contributor.author | MacNair, A | |
dc.contributor.author | Malik, Z | |
dc.contributor.author | Mason, MD | |
dc.contributor.author | Matheson, D | |
dc.contributor.author | Millman, R | |
dc.contributor.author | Parker, CC | |
dc.contributor.author | Ritchie, AWS | |
dc.contributor.author | Rush, H | |
dc.contributor.author | Russell, JM | |
dc.contributor.author | Brown, J | |
dc.contributor.author | Beesley, S | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Capaldi, L | |
dc.contributor.author | Gale, J | |
dc.contributor.author | Gibbs, S | |
dc.contributor.author | Lydon, A | |
dc.contributor.author | Nikapota, A | |
dc.contributor.author | Omlin, A | |
dc.contributor.author | O'Sullivan, JM | |
dc.contributor.author | Parikh, O | |
dc.contributor.author | Protheroe, A | |
dc.contributor.author | Rudman, S | |
dc.contributor.author | Srihari, NN | |
dc.contributor.author | Simms, M | |
dc.contributor.author | Tanguay, JS | |
dc.contributor.author | Tolan, S | |
dc.contributor.author | Wagstaff, J | |
dc.contributor.author | Wallace, J | |
dc.contributor.author | Wylie, J | |
dc.contributor.author | Zarkar, A | |
dc.contributor.author | Sydes, MR | |
dc.contributor.author | Parmar, MKB | |
dc.contributor.author | James, ND | |
dc.date.accessioned | 2019-12-06T15:05:41Z | |
dc.date.issued | 2019-12-01 | |
dc.identifier.citation | Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 30 (12), pp. 1992 - 2003 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3446 | |
dc.identifier.eissn | 1569-8041 | |
dc.identifier.doi | 10.1093/annonc/mdz396 | |
dc.description.abstract | BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS: We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. RESULTS: Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). CONCLUSIONS: The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden. | |
dc.format | Print | |
dc.format.extent | 1992 - 2003 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | OXFORD UNIV PRESS | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Disease Progression | |
dc.subject | Androgen Antagonists | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Proportional Hazards Models | |
dc.subject | Retrospective Studies | |
dc.subject | Aged | |
dc.subject | Middle Aged | |
dc.subject | Male | |
dc.subject | Docetaxel | |
dc.subject | Progression-Free Survival | |
dc.title | Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1093/annonc/mdz396 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2019-12 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Annals of oncology : official journal of the European Society for Medical Oncology | |
pubs.issue | 12 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Treatment Resistance | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Prostate and Bladder Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 30 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Academic Radiotherapy (Dearnaley) | |
icr.researchteam | Treatment Resistance | |
icr.researchteam | Prostate and Bladder Cancer Research | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | James, Nicholas | |